SUPN logo

Supernus Pharmaceuticals (SUPN) Return On Equity

Annual ROE

0.15%
-6.98%-97.90%

December 31, 2023


Summary


Performance

SUPN ROE Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherSUPNprofitabilitymetrics:

Quarterly ROE

6.32%
+5.76%+1028.57%

September 30, 2024


Summary


Performance

SUPN Quarterly ROE Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherSUPNprofitabilitymetrics:

ROE Formula

ROE =  Net Income
Shareholders Equity
✕ 100%

SUPN ROE Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year-97.9%+121.0%
3 y3 years-99.2%+121.0%
5 y5 years-99.5%+121.0%

SUPN ROE Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-year-97.9%at low-31.1%+474.0%
5 y5-year-99.3%at low-70.8%+474.0%
alltimeall time-100.0%+100.1%-97.7%+100.7%

Supernus Pharmaceuticals ROE History

DateAnnualQuarterly
Sep 2024
-
6.32%(+1028.6%)
Jun 2024
-
0.56%(-133.1%)
Mar 2024
-
-1.69%(-1307.1%)
Dec 2023
0.15%(-97.9%)
0.14%(-95.1%)
Sep 2023
-
2.86%(-41.8%)
Jun 2023
-
4.91%(-18.4%)
Mar 2023
-
6.02%(-16.3%)
Dec 2022
7.13%(+4.1%)
7.19%(+58.4%)
Sep 2022
-
4.54%(-35.5%)
Jun 2022
-
7.04%(-23.3%)
Mar 2022
-
9.18%(+34.4%)
Dec 2021
6.85%(-63.8%)
6.83%(-36.4%)
Sep 2021
-
10.74%(-21.5%)
Jun 2021
-
13.69%(-14.1%)
Mar 2021
-
15.93%(-16.5%)
Dec 2020
18.94%(-12.2%)
19.07%(-7.3%)
Sep 2020
-
20.58%(+2.9%)
Jun 2020
-
20.00%(-4.7%)
Mar 2020
-
20.99%(-3.1%)
Dec 2019
21.57%(-30.0%)
21.67%(-0.3%)
Sep 2019
-
21.73%(-6.1%)
Jun 2019
-
23.14%(-5.7%)
Mar 2019
-
24.55%(-16.6%)
Dec 2018
30.81%(+23.5%)
29.44%(+0.4%)
Sep 2018
-
29.33%(+0.9%)
Jun 2018
-
29.08%(+3.6%)
Mar 2018
-
28.07%(+12.3%)
Dec 2017
24.95%
24.99%(-9.2%)
Sep 2017
-
27.53%(-50.1%)
DateAnnualQuarterly
Jun 2017
-
55.12%(-4.2%)
Mar 2017
-
57.53%(-8.9%)
Dec 2016
65.21%(+200.9%)
63.15%(-3.5%)
Sep 2016
-
65.44%(+188.2%)
Jun 2016
-
22.71%(+31.7%)
Mar 2016
-
17.25%(+7.7%)
Dec 2015
21.67%(-173.6%)
16.02%(+21.7%)
Sep 2015
-
13.16%(+93.2%)
Jun 2015
-
6.81%(-32.9%)
Mar 2015
-
10.15%(-137.7%)
Dec 2014
-29.46%(-85.5%)
-26.95%(-74.7%)
Sep 2014
-
-106.41%(-47.9%)
Jun 2014
-
-204.05%(-30.6%)
Mar 2014
-
-293.90%(+15.1%)
Dec 2013
-202.72%(+46.8%)
-255.39%(+5.3%)
Sep 2013
-
-242.64%(+31.6%)
Jun 2013
-
-184.36%(+7.6%)
Mar 2013
-
-171.34%(-3.8%)
Dec 2012
-138.13%(-124.2%)
-178.16%(-165.5%)
Sep 2012
-
272.11%(-131.9%)
Jun 2012
-
-853.15%(+221.3%)
Mar 2012
-
-265.52%(+55.6%)
Dec 2011
569.89%(+556.7%)
-170.62%(-371.3%)
Sep 2011
-
62.88%(-6.6%)
Jun 2011
-
67.30%(+37.6%)
Mar 2011
-
48.91%(+128.9%)
Dec 2010
86.78%(-1261.7%)
21.37%(-45.1%)
Sep 2010
-
38.93%(-70.7%)
Dec 2009
-7.47%(-101.5%)
133.02%
Dec 2008
496.23%
-

FAQ

  • What is Supernus Pharmaceuticals annual return on equity?
  • What is the all time high annual ROE for Supernus Pharmaceuticals?
  • What is Supernus Pharmaceuticals annual ROE year-on-year change?
  • What is Supernus Pharmaceuticals quarterly return on equity?
  • What is the all time high quarterly ROE for Supernus Pharmaceuticals?
  • What is Supernus Pharmaceuticals quarterly ROE year-on-year change?

What is Supernus Pharmaceuticals annual return on equity?

The current annual ROE of SUPN is 0.15%

What is the all time high annual ROE for Supernus Pharmaceuticals?

Supernus Pharmaceuticals all-time high annual return on equity is 569.89%

What is Supernus Pharmaceuticals annual ROE year-on-year change?

Over the past year, SUPN annual return on equity has changed by -6.98% (-97.90%)

What is Supernus Pharmaceuticals quarterly return on equity?

The current quarterly ROE of SUPN is 6.32%

What is the all time high quarterly ROE for Supernus Pharmaceuticals?

Supernus Pharmaceuticals all-time high quarterly return on equity is 272.11%

What is Supernus Pharmaceuticals quarterly ROE year-on-year change?

Over the past year, SUPN quarterly return on equity has changed by +3.46% (+120.98%)